EP0655914A4 - Novel compositions. - Google Patents

Novel compositions.

Info

Publication number
EP0655914A4
EP0655914A4 EP93918819A EP93918819A EP0655914A4 EP 0655914 A4 EP0655914 A4 EP 0655914A4 EP 93918819 A EP93918819 A EP 93918819A EP 93918819 A EP93918819 A EP 93918819A EP 0655914 A4 EP0655914 A4 EP 0655914A4
Authority
EP
European Patent Office
Prior art keywords
pct
agonists
sec
erectogenic
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93918819A
Other languages
German (de)
French (fr)
Other versions
EP0655914B1 (en
EP0655914A1 (en
Inventor
Cesar Roberto Dias Nahoum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAHOUM, CESAR ROBERTO DIAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0655914A1 publication Critical patent/EP0655914A1/en
Publication of EP0655914A4 publication Critical patent/EP0655914A4/en
Application granted granted Critical
Publication of EP0655914B1 publication Critical patent/EP0655914B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PCT No. PCT/BR93/00027 Sec. 371 Date Feb. 15, 1995 Sec. 102(e) Date Feb. 15, 1995 PCT Filed Aug. 18, 1993 PCT Pub. No. WO94/04120 PCT Pub. Date Mar. 3, 1994The present invention involves the novel use of H2 and H3 agonists, as erectogenic agents in the treatment of male and female sexual dysfunction in an animal, including humans. The H2 and H3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally. The method of use may also include a second therapeutic agent which either facilitates, potentiates or is erectogenic. The second agent may be administered sequentially or contemporaneously with either the H2 or H3 agonist.
EP93918819A 1992-08-21 1993-08-18 Use of Histamine-2 agonists for treatment of sexual dysfunction Expired - Lifetime EP0655914B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR929203277A BR9203277A (en) 1992-08-21 1992-08-21 USE OF ERETOGENIC DRUGS AND THEIR APPLICATION METHODOLOGIES
BR9203277 1992-08-21
PCT/BR1993/000027 WO1994004120A2 (en) 1992-08-21 1993-08-18 Methods of treating sexual dysfunction in animals with and h agonist

Publications (3)

Publication Number Publication Date
EP0655914A1 EP0655914A1 (en) 1995-06-07
EP0655914A4 true EP0655914A4 (en) 1998-04-22
EP0655914B1 EP0655914B1 (en) 2003-02-26

Family

ID=4054796

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93918819A Expired - Lifetime EP0655914B1 (en) 1992-08-21 1993-08-18 Use of Histamine-2 agonists for treatment of sexual dysfunction

Country Status (13)

Country Link
US (1) US5908853A (en)
EP (1) EP0655914B1 (en)
JP (1) JP2002510277A (en)
KR (1) KR100331754B1 (en)
AT (1) ATE233091T1 (en)
BR (1) BR9203277A (en)
CA (1) CA2142875A1 (en)
DE (1) DE69332713D1 (en)
NZ (1) NZ255278A (en)
OA (1) OA10251A (en)
TW (1) TW418090B (en)
WO (1) WO1994004120A2 (en)
ZA (1) ZA936118B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
FR2748658B1 (en) * 1996-05-15 2000-08-18 Biotec Centre Sa USE OF "ALPHA-BLOCKING" COMPOUNDS, PARTICULARLY MOXISYLYTE AND / OR DERIVATIVES THEREOF FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS BY BALAN TRANSMUCOSAL ROUTE
GR1002847B (en) * 1997-05-06 1998-01-27 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
DE19728103A1 (en) * 1997-07-02 1999-01-07 Winfried Dr Med Heinicke Composition for treatment of erectile dysfunction
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
GB9802078D0 (en) * 1998-01-30 1998-03-25 Futura Medical Limited Preparation for treatment of erectile dysfunction
FR2774593B1 (en) * 1998-02-12 2000-05-05 Philippe Gorny OBTAINING A MEDICINE TO COMBAT FEMALE SEXUAL DYSFUNCTIONS
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
GR1003199B (en) 1998-08-14 1999-09-01 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic threatment of problemes related to the female sexual malfunction
FR2786699B1 (en) * 1998-12-02 2002-10-04 Philippe Gorny MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
DE60131644T2 (en) 2000-05-09 2008-10-30 Nitromed, Inc., Lexington INFRARED THERMOGRAPHY AND TREATMENT OF SEXUAL DYSFUNCTIONS
CA2409592A1 (en) * 2000-05-22 2001-11-29 Illana Gozes Pharmceutical compositions comprising vip-related peptides for the treatment of sexual disorders
WO2002064212A1 (en) * 2001-02-13 2002-08-22 Cornell Research Foundation, Inc. Method and compositions for reducing cardiac dysfunctions with a selective histamine h3 receptor agonist
US20030195186A1 (en) * 2002-04-10 2003-10-16 University Of Florida Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US7622844B1 (en) * 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
CN101340884A (en) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 Methods for the treatment of hyperhidrosis
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US20140121256A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
CA3050082A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013659A (en) * 1973-07-13 1977-03-22 Smith Kline & French Laboratories Limited Certain n,n'-disubstituted guanidine compounds and their use
US4126670A (en) * 1976-03-29 1978-11-21 Smith Kline & French Laboratories Limited Method of stimulating histamine H2 -receptors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4293562A (en) * 1979-07-02 1981-10-06 Arnold Ritter Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DE3413371C1 (en) * 1984-04-09 1986-01-02 Esselte Pendaflex Corp., Garden City, N.Y. label
US4840952A (en) * 1985-11-01 1989-06-20 Bristol-Myers Company Method for treatment of male impotence
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
EP0266968A3 (en) * 1986-11-03 1988-08-24 Gérard G. Cohen Gelled ointment of vasodilating agent
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
IT1221826B (en) * 1988-06-08 1990-07-12 Medico Harvey Srl Centro PREPARED FOR TOPICAL USE FOR THE THERAPEUTIC TREATMENT OF IMPOTENTIA COEUNDI
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (en) * 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
US4931445A (en) * 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
DE3913954A1 (en) * 1989-04-27 1990-10-31 Stief Georg MEDICINES FOR TREATING ERECTILE DYSFUNCTIONS
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (en) * 1989-07-11 1991-09-27 Virag Ronald VASO-ACTIVE MEDICINE
IT1252603B (en) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
IT1247678B (en) * 1990-05-31 1994-12-28 Alberto Reale METHOD FOR THE TREATMENT OF MALE ERECTIVE IMPOTENCE
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
DK0484581T3 (en) * 1990-11-08 1994-10-24 Boehringer Mannheim Gmbh Use of thromboxane A2 receptor antagonists to prevent degenerative processes in the penile tissue
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013659A (en) * 1973-07-13 1977-03-22 Smith Kline & French Laboratories Limited Certain n,n'-disubstituted guanidine compounds and their use
US4126670A (en) * 1976-03-29 1978-11-21 Smith Kline & French Laboratories Limited Method of stimulating histamine H2 -receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAIKAN ET AL.: "EFFECT OF HISTAMINE ON THE HUMAN PENIS MUSCLE IN VITRO", EUR. J. PHARMACOLOGY, vol. 45, 1977, pages 261 - 265, XP002044007 *

Also Published As

Publication number Publication date
WO1994004120A2 (en) 1994-03-03
EP0655914B1 (en) 2003-02-26
WO1994004120A3 (en) 1994-05-26
OA10251A (en) 1997-10-07
JP2002510277A (en) 2002-04-02
ZA936118B (en) 1995-04-20
AU678996B2 (en) 1997-06-19
US5908853A (en) 1999-06-01
KR100331754B1 (en) 2002-10-04
BR9203277A (en) 1994-03-01
EP0655914A1 (en) 1995-06-07
AU4937193A (en) 1994-03-15
KR950702823A (en) 1995-08-23
TW418090B (en) 2001-01-11
NZ255278A (en) 1999-05-28
CA2142875A1 (en) 1994-03-03
DE69332713D1 (en) 2003-04-03
ATE233091T1 (en) 2003-03-15

Similar Documents

Publication Publication Date Title
EP0655914A4 (en) Novel compositions.
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
GR3024134T3 (en) Secondary amines as antidiabetic and antiobesity agents
EA200001044A2 (en) Nep inhibitors for the treatment of female sexual disfunction
KR960701051A (en) IMIDAZOPYRIDINES AND THEIR USE IN TREATING CASTROINTESTINAL DISEASES
EP0415613A3 (en) Use of sertraline for the treatment of premature ejaculation
DE69634269D1 (en) METHOD FOR MODULATING MICROCIRCULATION
GB9317636D0 (en) Use of dexmedetomidine
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
GR3024157T3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
SE9402880D0 (en) New peptide derivatives
MX9401406A (en) SELECTIVE ADENOSINE RECEIVING AGENTS TO INTENSIFY KNOWLEDGE.
ES2157984T3 (en) USE OF 4&#39;-IODO-4&#39;-DEOXIDOXORRUBICINE FOR THE TREATMENT OF AMIDOIDOSIS.
ES2097816T5 (en) PRODUCT AND ITS USE FOR THE TREATMENT OF CATABOLIC STATES THAT INCLUDE AUTHENTIC IFG-1 AND NUTRIENT HYPOCALORIC QUANTITIES.
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
RU95119067A (en) METHOD FOR STIMULING THE BREEDING CATTLE FUNCTION
MX9708044A (en) Stress regulator for animals.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE DK ES GB LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT CH DE DK ES GB LI LU NL PT SE

17Q First examination report despatched

Effective date: 19990303

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/415 A, 7A 61K 31/155 B, 7A 61K 31/17 B, 7A 61K 31/44 B, 7A 61P 15/10 B

RTI1 Title (correction)

Free format text: USE OF HISTAMINE-2 AGONISTS FOR TREATMENT OF SEXUAL DYSFUNCTION

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NAHOUM, CESAR ROBERTO DIAS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAHOUM, CESAR ROBERTO DIAS

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT CH DE DK ES GB LI LU NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030226

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030226

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030226

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030226

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69332713

Country of ref document: DE

Date of ref document: 20030403

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030526

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030526

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030527

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030818

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030818

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030828

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20031127

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20030818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012290

Country of ref document: HK